US FDA advisers recommends Novavax Covid vaccine for adults
Advisers to the United States Food and Drug Administration (FDA) have overwhelmingly backed the authorization of Novavax Inc's COVID-19 vaccine for adults. A panel of outside vaccine experts on Tuesday voted 21-0 with one abstention, recommending the use of the jab for people aged 18 and above. The FDA will now decide whether to greenlight Novavax as the fourth coronavirus vaccine for adults in the US. A decision is not expected immediately. Novavax Chief Commercial Officer John Trizzino said the documents with details on the shot's manufacturing process were submitted to the agency last week and that they were still being reviewed. "We hopefully expect to have product in the US in our warehouse by the end of June," he said in an interview. Trizzino said that the Maryland-based company has plans to ship millions of doses made by its partner, the Serum Institute of India, as soon as the FDA gives an approval. The protein vaccine made by latecomer Novavax employs technology that has been used for decades to fight diseases like influenza. The drugmaker hopes that the more traditional type of jab could become a choice among some vaccine skeptics in the country.